Eve Health Group Ltd

EVE Health Group (ASX: EVE) has received stong support from sophisticated and professional investors for a capital raising aimed at accelerating the commercial rollout of its lead pharmaceutical products Dyspro and Libbo. When the placement attracted bids in excess of the $1 million EVE initially sought, the company increased the offer to $1.1m, the maximum capacity […]

EVE Health Group (ASX: EVE) has prescribed its Dyspro cannabinoid-based gummy for the treatment of dysmenorrhoea and endometriosis to Australian patients for the first time. EVE issued the drug under the Therapeutic Goods Administration’s Special Access Scheme, marking the company’s transition from production and distribution to real-world patient access. The milestone follows the company’s successful completion […]

Discover Australia’s Next Wave of Growth The Spark Plus Australian Equities Day 2025 is more than just another investor showcase—it’s your gateway to the next generation of ASX growth stories. Across 18 power-packed presentations, this event brings together some of Australia’s most ambitious companies, each sitting at the cutting edge of their sectors and driving […]

EVE Health Group (ASX: EVE) has commenced dispatching its proprietary women’s health product Dyspro to distribution partners in preparation for an Australian launch. Dyspro is a first-in-class, cannabinoid-based gummy for the symptoms of dysmenorrhoea (painful menstruation) and endometriosis, two of the most prevalent and under-addressed conditions in women’s health. Following the completion of commercial-scale production, […]